CAS: 2143096-93-7
| Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
|---|---|---|---|---|
 | Navitoclax-piperazine REF: TM-T12186CAS: 2143096-93-7 | 99.11% - 99.82% | 153,00 €~1.500,00 € | Di 10 Dez 24 |
 | Navitoclax-piperazine REF: 3D-TKD09693CAS: 2143096-93-7 | Min. 95% | 324,00 €~3.826,00 € | Di 21 Jan 25 |
Navitoclax-piperazine
CAS:2143096-93-7
Navitoclax-piperazine (ABT-263-piperazine) is an inhibitor of B-cell lymphoma extra large (BCL-XL).
Formel:
C47H56ClF3N6O5S3
Reinheit:
99.11% - 99.82%
Farbe und Form:
Solid
Molekulargewicht:
973.63
Ref: TM-T12186
| 1mg | 153,00 € | ||
| 5mg | 302,00 € | ||
| 10mg | 513,00 € | ||
| 25mg | 809,00 € | ||
| 50mg | 1.111,00 € | ||
| 100mg | 1.500,00 € | ||
| 1mL*10mM (DMSO) | 529,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 10. Dezember 2024
Navitoclax-piperazine
CAS:2143096-93-7
Navitoclax-piperazine is a cell biology research tool that inhibits protein interactions. It is a small …
Formel:
C47H56ClF3N6O5S3
Reinheit:
Min. 95%
Molekulargewicht:
973.6 g/mol
Ref: 3D-TKD09693
| 2mg | 780,00 € | ||
| 5mg | 1.174,00 € | ||
| 10mg | 1.594,00 € | ||
| 25mg | 2.551,00 € | ||
| 50mg | 3.826,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Dienstag 21. Januar 2025
